← Back to Clinical Trials
Recruiting NCT06679751

NCT06679751 Infectious Disease (ID) Testing OUtreach in Carceral Hubs

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06679751
Status Recruiting
Phase
Sponsor Boston Medical Center
Condition HIV Infections
Study Type OBSERVATIONAL
Enrollment 75 participants
Start Date 2025-06-23
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
ID-TOUCH

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 75 participants in total. It began in 2025-06-23 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pilot feasibility study represents part 3 of a larger R61 study, where the investigators will follow a cohort about their experiences with human immunodeficiency virus (HIV) testing. This project aims to assess the effectiveness of an intervention at two jail sites in the Boston area: South Bay House of Corrections and Nashua Street Jail implemented in January of 2025 that is aimed at improving HIV testing practices and HIV treatment in those carceral facilities. This implementation was developed independently of the investigators' study activities. The jails worked to develop changes in their electronic health record to offer HIV testing at various points in their intake and physical exam process. HIV care was not well-integrated with the jails' existing intake and healthcare administration systems and medications for opioid use disorder (MOUD) program. The investigators will evaluate the intervention the jails developed to address these issues. The outcomes of interest are more implementation than effectiveness outcomes. The primary goal of this study is to identify existing barriers in the carceral healthcare setting that prevent the improvement of HIV testing and treatment.

Eligibility Criteria

Inclusion Criteria: * Incarcerated at South Bay House of Corrections or Nashua Street Jail * Participant Report that they will be leaving jail within 1 month. * Participant must be comfortable speaking in the English Language * Has Opioid Use Disorder (OUD) indicated by participation in Medications for Opioid Use Disorder (MOUD) program and/or self-report Exclusion Criteria: * Cognitive ability that prevents obtained consent or completion of study activities (defined through Research Assistant (RA) determination)

Contact & Investigator

Central Contact

Alysse Wurcel, MD MS

✉ Alysse.Wurcel@bmc.org

📞 617-414-5951

Principal Investigator

Alysse Wurcel, MD MS

PRINCIPAL INVESTIGATOR

Boston Medical Center

Frequently Asked Questions

Who can join the NCT06679751 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06679751 currently recruiting?

Yes, NCT06679751 is actively recruiting participants. Contact the research team at Alysse.Wurcel@bmc.org for enrollment information.

Where is the NCT06679751 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06679751 clinical trial?

NCT06679751 is sponsored by Boston Medical Center. The principal investigator is Alysse Wurcel, MD MS at Boston Medical Center. The trial plans to enroll 75 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology